Infective Endocarditis Management: ESC/AHA 2023 Guidelines

Abstract

Infective endocarditis (IE) remains a severe microbial infection of the endocardium with high morbidity and mortality, necessitating rapid, guideline-driven management. 

This article summarizes the core principles and recent updates from the 2023 European Society of Cardiology (ESC) and American Heart Association (AHA) guidelines, focusing on an integrated Heart Team approach.

 Key diagnostic advancements include the increased utility of multimodality imaging, particularly 18F-FDG PET/CT and cardiac CT, which significantly enhance sensitivity for diagnosing prosthetic valve IE (PVIE). Pharmacologic therapy remains centered on prolonged, organism-specific intravenous antibiotics. 

Crucially, the guidelines reinforce the absolute indications for surgery, emphasizing the need for urgent intervention in cases complicated by acute heart failure, uncontrolled local infection, or large vegetations with recurrent emboli. Prevention focuses on targeted antibiotic prophylaxis for high-risk patients undergoing specific dental procedures. 

Ultimately, optimizing outcomes in IE depends on timely diagnosis, optimal antimicrobial management, and prompt consultation for surgical intervention.

Introduction

Infective Endocarditis (IE) represents a high-acuity cardiovascular disease characterized by microbial invasion and destruction of native or prosthetic heart valves, the endocardium, or implanted cardiac devices. 

Despite advancements in antimicrobial therapy, imaging technology, and surgical techniques, IE continues to carry significant in-hospital mortality rates ranging from 15% to 30%. 

The epidemiologic profile of IE is evolving, marked by an increasing incidence in older patients with underlying degenerative valve disease, the rise of healthcare-associated infections, and a persistently high burden in individuals with intravenous drug use. 

Given the diverse clinical presentations, the potential for catastrophic embolic events, and the rapid onset of hemodynamic compromise (e.g., acute heart failure), a unified, evidence-based approach to prevention, accurate diagnosis, and timely management is paramount. 

The latest international guidelines from the ESC and AHA provide updated, Class I recommendations emphasizing rapid risk stratification, the indispensable role of the multidisciplinary Heart Team, and refined criteria for the critical decision of surgical intervention. 

This review synthesizes these core updates to provide healthcare professionals with an authoritative framework for managing this complex condition.

Risk Stratification and Prevention

The cornerstone of infective endocarditis (IE) prevention involves accurate risk stratification to identify patients who derive a clear benefit from antibiotic prophylaxis before bacteremia-inducing procedures. 

The majority of IE cases are community-acquired and not preventable by standard antibiotic regimens; therefore, current guidelines strictly limit prophylaxis to the highest-risk groups.

High-Risk Groups for Endocarditis Prophylaxis

Antibiotic prophylaxis is warranted only for individuals undergoing specific high-risk procedures (primarily dental) who have the underlying cardiac conditions associated with the highest likelihood of adverse outcomes from IE. These Class I indications include:

• Patients with a prosthetic cardiac valve or prosthetic material used for cardiac valve repair.
  
  
• Individuals with a history of previous IE.
  
  
• Patients with specific types of congenital heart disease (CHD):
  • Unrepaired cyanotic CHD, including palliative shunts and conduits.
    
    
  • Completely repaired CHD with prosthetic material or device, during the first six months after the procedure.
    
    
  • Repaired CHD with residual defects at the site or adjacent to the site of a prosthetic patch or device.
    
    
• Cardiac transplant recipients who develop valvulopathy.
  
  

The guidelines emphasize the general importance of maintaining rigorous oral hygiene for all cardiac patients, as this non-pharmacologic measure is considered the most effective way to reduce the overall lifetime risk of bacteremia.

Prophylaxis Recommendations (Class I Indications)

Antibiotic prophylaxis is recommended only for the high-risk patient groups listed above when they undergo all dental procedures that involve manipulation of gingival tissue or the periapical region of teeth, or perforation of the oral mucosa.

• Standard Regimen (Oral): Amoxicillin is the drug of choice for patients not allergic to penicillin. A single dose of 2  g is administered 30 to 60 minutes before the procedure.
  
  
• Alternative Regimen (Penicillin Allergy): Alternatives include Clindamycin (600 mg), Cephalexin (2 g), or Azithromycin/Clarithromycin (500 mg).
  
  

For non-dental procedures, prophylaxis is generally not recommended for genitourinary or gastrointestinal tract procedures, unless the procedure is performed in an area of established infection. 

This reflects the limited evidence demonstrating efficacy and the broader concern regarding the promotion of antibiotic resistance.

Diagnostic Strategy: Applying Modified Duke Criteria

The diagnosis of infective endocarditis (IE) relies heavily on integrating clinical, microbiological, and imaging findings, primarily through the established Modified Duke Criteria. 

These criteria classify IE into Definite, Possible, or Rejected categories based on the presence of Major and Minor criteria. Prompt and accurate diagnosis is critical, as delays in treatment are directly linked to adverse outcomes.

Integrating Advanced Imaging in Diagnosis

Echocardiography remains the foundational imaging modality. Transthoracic Echocardiography (TTE) is the initial screen, but Transesophageal Echocardiography (TEE) is significantly more sensitive (up to 90%) for detecting vegetations, abscesses, and prosthetic valve complications, especially when TTE results are non-diagnostic, technically limited, or in the presence of a prosthetic valve. TEE is a Class I recommendation in nearly all cases of suspected IE.

The 2023 guidelines underscore the growing utility of Multimodality Imaging for challenging cases, particularly prosthetic valve IE (PVIE):

• 18F-FDG PET/CT: This functional imaging technique is recommended (Class IIa) for diagnosing PVIE, particularly when the prosthetic valve has been in place for more than one year. It detects abnormal metabolic activity around the prosthetic material, indicating active infection.
  
  
• Cardiac CT: Useful for detecting paravalvular complications like abscesses, pseudoaneurysms, and fistula formation, especially when echocardiography is inconclusive or challenging.
  
  

Microbiological Evaluation and Blood Cultures

Obtaining three separate sets of blood cultures from different venipuncture sites before initiating empirical antimicrobial therapy is a Class I recommendation. Each set should include aerobic and anaerobic bottles. The microbiological results are essential for shifting from empirical to targeted therapy, which is the primary driver of successful treatment.

In cases where standard cultures are negative, but clinical suspicion remains high (Culture-Negative IE), special attention must be paid to:

• Fastidious Organisms: Such as HACEK group, Coxiella burnetii, or Bartonella species, requiring specialized serologic testing or prolonged incubation periods.
  
  
• Prior Antibiotic Exposure: Leading to non-diagnostic cultures, necessitating serology or PCR assays on explanted valve tissue if surgery is performed.
  
  

Pharmacologic Management: Key Therapeutic Principles

The treatment of infective endocarditis (IE) is primarily antimicrobial, demanding prolonged courses of high-dose intravenous antibiotics to eradicate the dense bacterial biofilm residing within the vegetations. 

Therapy is guided by rapid identification of the causative organism and its antimicrobial susceptibility, necessitating close collaboration between cardiology and infectious disease specialists.

Empirical vs. Targeted Antibiotic Regimens

Initial treatment must be empirical, administered immediately after obtaining blood cultures and tailored to the clinical setting, common causative pathogens, and the presence of prosthetic material.

• Native Valve IE (Community-Acquired): Empiric therapy often targets Staphylococci (including Methicillin-Resistant S. aureus [MRSA] if suspicion is high), Streptococci, and Enterococci. A common regimen includes a beta-lactam (e.g., Ampicillin/Sulbactam or Ceftriaxone) combined with an Aminoglycoside (e.g., Gentamicin) or Vancomycin if MRSA is suspected.
  
  
• Prosthetic Valve IE (PVIE) or Healthcare-Associated IE: These often involve more resistant organisms. Empiric therapy is typically broader, utilizing a combination like Vancomycin plus an Aminoglycoside (Gentamicin) plus an Antistaphylococcal beta-lactam (e.g., Cefepime or Piperacillin/Tazobactam).
  
  

Once the organism is identified and sensitivities are known, therapy must transition promptly to a targeted regimen. The total duration of therapy is typically 4  to  6  weeks from the first day of negative blood cultures, depending on the organism, location (native vs. prosthetic valve), and complications. Therapeutic drug monitoring (TDM), especially for agents like Vancomycin and Aminoglycosides, is critical to ensure efficacy and minimize nephrotoxicity.

Specific Challenges in Drug-Resistant Organisms (e.g., MRSA)

The management of IE caused by drug-resistant organisms, particularly MRSA, presents significant challenges:

• MRSA IE: Vancomycin is the cornerstone of therapy. However, its effectiveness relies on maintaining adequate trough concentrations (15  to  20  mg/L) without inducing renal injury. Alternatives like Daptomycin or Linezolid may be considered.
  
  
• Prosthetic Valve Staphylococcal IE: The addition of Rifampicin is a Class I recommendation for the first 3  to  14 days of the PVIE treatment course, typically combined with a cell-wall active agent (e.g., Vancomycin) and Gentamicin. Rifampicin is added to penetrate the biofilm and should never be used as monotherapy.
  
  

Practice Highlight: Antimicrobial Selection

• Targeted therapy is always preferred over empirical therapy.
  
  
• Antibiotics must be bactericidal against the infecting organism.
  
  
• For Left-Sided IE due to susceptible Streptococcus spp., a two-week regimen of Penicillin G or Ceftriaxone plus Gentamicin is an acceptable alternative to a four-week monotherapy regimen in specific, low-risk cases.
  
  

Surgical Intervention: When and Why (Mandatory Criteria)

The decision for surgical intervention in infective endocarditis (IE) is a cornerstone of effective management, with timing often critically determining patient survival. The approach must be individualized and determined by the Heart Team. Surgery aims to remove the source of infection, repair or replace the damaged valve, and restore hemodynamic stability.

Absolute (Urgent/Emergency) Indications for Surgery

Guidelines provide clear Class I recommendations for surgical intervention, typically categorized by the urgency required:

• Heart Failure (HF): The most common indication for urgent or emergency surgery. This includes acute, severe valvular regurgitation (aortic or mitral) leading to signs of hemodynamic compromise (pulmonary edema, cardiogenic shock).
  
  
• Uncontrolled Local Infection: Persistence of infection despite optimal antibiotic therapy. This includes:
  
  
  • Failure to control infection (e.g., persistent bacteremia after 7  to  10 days of appropriate therapy).
    
    
  • Periannular complications (abscess, pseudoaneurysm, fistula formation) confirmed by TEE or CT/PET.
    
    
• Prevention of Systemic Emboli: Surgery is indicated when there is a high risk of recurrent embolism, particularly following one or more embolic events. Key criteria include:
  • Large vegetations on the mitral valve (> 10  mm), especially if associated with severe mitral regurgitation.
    
    
  • Large vegetations (> 10  mm) on the aortic valve, particularly if mobile.
    
    

Timing and Prognostic Impact of Surgery

Surgical timing is classified into three categories:

1. Emergency Surgery: Within 24 hours (e.g., refractory cardiogenic shock, acute severe regurgitation causing acute pulmonary edema).
   
   
2. Urgent Surgery: Within a few days, typically 1  to  7 days (e.g., uncontrolled infection, prevention of recurrent embolism in stable patients).
   
   
3. Elective Surgery: After completion of the full antibiotic course (e.g., patients who have been clinically and microbiologically stable throughout treatment but have residual valve damage).
   
   

Practice Highlight: Neurologic Complications and Timing Surgery should generally be deferred for 3  to  4  weeks after a major ischemic stroke or intracranial hemorrhage unless there is an emergency surgical indication (e.g., refractory heart failure). This delay minimizes the risk of converting an ischemic stroke into a hemorrhagic one post-bypass.

Management of Complications and Special Populations

IE is characterized by a high burden of systemic and localized complications, significantly impacting prognosis.

• Neurologic Complications: Ischemic stroke is common. Surgery should generally be deferred for 3 to 4 weeks following an ischemic event to reduce the risk of hemorrhagic conversion.
  
  
• Right-Sided Endocarditis (RSE): Predominantly affects the tricuspid valve, strongly associated with Intravenous Drug Use (IDU). RSE often responds to medical therapy alone; surgery is reserved for persistent septic emboli or heart failure.
  
  
• Device-Related Endocarditis: Complete device removal (generator and all leads) is a Class I recommendation for cure, followed by a 4 to 6-week course of targeted antimicrobial therapy.
  
  

Clinical Practice Summary and Key Takeaways

The successful management of infective endocarditis (IE) hinges on the seamless integration of prevention, advanced diagnostics, and timely therapeutic interventions as dictated by the latest ESC/AHA guidelines. The central tenet remains the deployment of a Heart Team to optimize decision-making.

• Risk Mitigation is Targeted: Prophylaxis is highly focused on the highest-risk cardiac conditions undergoing specific high-risk dental procedures.
  
  
• Diagnosis is Multimodality: The Modified Duke Criteria remain the standard, but diagnosis increasingly relies on TEE, complemented by  18F-FDG PET/CT or cardiac CT for complex cases (e.g., PVIE).
  
  
• Antimicrobial Strategy is Prolonged and Targeted: Treatment requires prolonged (4 to 6 weeks) intravenous bactericidal therapy, with TDM used to optimize drug levels. Rifampicin is key in PVIE.
  
  
• Surgery is Life-Saving: Urgent surgery is mandated for patients with acute severe heart failure, uncontrolled local infection, and large vegetations causing recurrent emboli.